Tag - ACIU

Developments

AC Immune announces positive interim results from study of ACI-7104.056 in Parkinson’s

AC Immune (NASDAQ:ACIU) announced positive interim safety and immunogenicity data from its Phase 2 VacSYn clinical trial, evaluating ACI-7104.056 as a treatment for patients with early Parkinson’s disease. The company...

November 15, 2024

Developments

AC Immune semorinemab fails Phase 2 Alzheimer’s disease trial

AC Immune (NASDAQ:ACIU) reported disappointing topline results from a Phase 2 trial evaluating semorinemab for the treatment of early Alzheimer’s disease (AD). Semorinemab, an anti-tau antibody, did not meet its primary...

September 23, 2020

Developments

AC Immune initiates second dosing group in Phase 1b/2a Alzheimer’s disease vaccine trial

AC Immune (NASDAQ:ACIU) initiated the second highest dosing group in a Phase 1b/2a clinical trial evaluating its anti-phospho-tau vaccine in patients with early Alzheimer’s disease (AD). The vaccine, called ACI-35...

July 16, 2020

Tag - ACIU

AC Immune announces positive interim results from study of ACI-7104.056 in Parkinson’s

AC Immune semorinemab fails Phase 2 Alzheimer’s disease trial

AC Immune initiates second dosing group in Phase 1b/2a Alzheimer’s disease vaccine trial

General

More